157 related articles for article (PubMed ID: 32056089)
1. HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma.
da Cunha Jaeger M; Ghisleni EC; Cardoso PS; Siniglaglia M; Falcon T; Brunetto AT; Brunetto AL; de Farias CB; Taylor MD; Nör C; Ramaswamy V; Roesler R
J Mol Neurosci; 2020 Jun; 70(6):981-992. PubMed ID: 32056089
[TBL] [Abstract][Full Text] [Related]
2. Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
Badodi S; Pomella N; Lim YM; Brandner S; Morrison G; Pollard SM; Zhang X; Zabet NR; Marino S
Neuro Oncol; 2022 Aug; 24(8):1273-1285. PubMed ID: 35213723
[TBL] [Abstract][Full Text] [Related]
3. FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.
Manoranjan B; Wang X; Hallett RM; Venugopal C; Mack SC; McFarlane N; Nolte SM; Scheinemann K; Gunnarsson T; Hassell JA; Taylor MD; Lee C; Triscott J; Foster CM; Dunham C; Hawkins C; Dunn SE; Singh SK
Stem Cells; 2013 Jul; 31(7):1266-77. PubMed ID: 23592496
[TBL] [Abstract][Full Text] [Related]
4. Astrocytes influence medulloblastoma phenotypes and CD133 surface expression.
Gronseth E; Gupta A; Koceja C; Kumar S; Kutty RG; Rarick K; Wang L; Ramchandran R
PLoS One; 2020; 15(7):e0235852. PubMed ID: 32628717
[TBL] [Abstract][Full Text] [Related]
5. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
6. Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
PLoS One; 2016; 11(7):e0154111. PubMed ID: 27367907
[TBL] [Abstract][Full Text] [Related]
7. Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
Jaeger M; Ghisleni EC; Fratini L; Brunetto AL; Gregianin LJ; Brunetto AT; Schwartsmann G; de Farias CB; Roesler R
Childs Nerv Syst; 2016 Jan; 32(1):61-4. PubMed ID: 26590027
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.
Nör C; Sassi FA; de Farias CB; Schwartsmann G; Abujamra AL; Lenz G; Brunetto AL; Roesler R
Mol Neurobiol; 2013 Dec; 48(3):533-43. PubMed ID: 23516101
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells.
Chang CJ; Chiang CH; Song WS; Tsai SK; Woung LC; Chang CH; Jeng SY; Tsai CY; Hsu CC; Lee HF; Huang CS; Yung MC; Liu JH; Lu KH
Childs Nerv Syst; 2012 Mar; 28(3):363-73. PubMed ID: 22249380
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
11. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
12. Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma.
Badodi S; Dubuc A; Zhang X; Rosser G; Da Cunha Jaeger M; Kameda-Smith MM; Morrissy AS; Guilhamon P; Suetterlin P; Li XN; Guglielmi L; Merve A; Farooq H; Lupien M; Singh SK; Basson MA; Taylor MD; Marino S
Cell Rep; 2017 Dec; 21(10):2772-2784. PubMed ID: 29212025
[TBL] [Abstract][Full Text] [Related]
13. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
14. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.
Chen KH; Hsu CC; Song WS; Huang CS; Tsai CC; Kuo CD; Hsu HS; Tsai TH; Tsai CY; Woung LC; Chiou SH; Lu KH; Chen YW
Childs Nerv Syst; 2010 Nov; 26(11):1605-12. PubMed ID: 20526717
[TBL] [Abstract][Full Text] [Related]
16. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
17. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
[TBL] [Abstract][Full Text] [Related]
18. Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1.
Chen J; Wang Y; Zhuo L; Liu Z; Liu T; Li W; Cai Y; Zheng H
Mol Carcinog; 2017 Oct; 56(10):2267-2278. PubMed ID: 28543447
[TBL] [Abstract][Full Text] [Related]
19. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
20. Laminin-adherent versus suspension-non-adherent cell culture conditions for the isolation of cancer stem cells in the DAOY medulloblastoma cell line.
de la Rosa J; Sáenz Antoñanzas A; Shahi MH; Meléndez B; Rey JA; Castresana JS
Tumour Biol; 2016 Sep; 37(9):12359-12370. PubMed ID: 27306215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
